Monday, August 8, 2022
As we begin rolling out injectable cabotegravir (CAB) as PrEP, what lessons have we learned from the first 10 years of oral PrEP implementation? How can we do better with a new PrEP intervention that offers new opportunities and distinct challenges? Learn more in this Choice Agenda webinar.
Featuring Rachel Baggaley, Caroline Carnevale, Monica Gandhi and Mitchell Warren
Friday, October 7, 2022
Very high STI prevalence is being observed globally. Doxycycline post-exposure prophylaxis (dPEP) has been proposed as an STI prevention strategy to reduce chlamydia, syphilis, and possibly gonorrhea, and trials are ongoing among cisgender gay and bisexual men as well as African cisgender women. Learn about the latest scientific data and more during this Choice Agenda webinar.
Featuring Dr. Connie Celum, Jennifer Mahn, Dr. Victor Omollo, Rodney Perkins and Dr. Jenell Stewart
Wednesday, December 14, 2022
During this webinar, panelists explored the need for Pregnant and Lactating Populations (PLP) to be included HIV prevention clinical and implementation research
Speakers included Dr. Elaine Abrams, Raniyah Copeland, Dr. Lisa Noguchi and Dr. Lynda Stranix-Chibanda. The discussion was moderated by Dr. Dvora Joseph Davey.
The world is grappling with the far-reaching impacts of the COVID-19 pandemic and the HIV prevention field is no different. Most trials investigating new biomedical HIV prevention products have paused, citing concerns for the safety of trial participants and the study teams.
How COVID-19 is impacting research varies by trial and site, and efforts are ongoing to minimize impact on trial timelines and data. AVAC will continue to monitor developments—watch this space.
This table is a work in progress, as this is an incredibly dynamic landscape. Over the past month, the scientific community has accelerated development of COVID-19 diagnostics, therapeutics and a potential vaccine. This document also links to a number of resources available to track these developments.
In addition, a collaborative project of the COVID-19 Working Group NY, the PrEP4All Collaboration and Treatment Action Group offers concise overviews and analyses of key research areas.
This document is to help advocates with links to the latest information about COVID-19, including information on its prevention, transmission, relationship to HIV and research that’s underway. Many of the links below are constantly updated so please click through for the latest.
PrEP introduction is gaining traction around the world. Check out AVAC’s graphic showing global totals, and the uptick in implementation studies, regulatory approvals, global recommendations and more.
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the AIDS vaccine field.
Monday, February 20 at 7:00–8:00am PT
AVAC, the CROI Community Liaison Subcommittees, European AIDS Treatment Group, and other partners hosted virtual Margarita Breakfast Clubs (MBCs) for the 2023 CROI meeting. Speaker details, recording, and resources for the first 2023 MBC below.